Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Published:2014-05-29 Issue:22 Volume:123 Page:3406-3413
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Flinn Ian W.¹,Kahl Brad S.²,Leonard John P.³,Furman Richard R.³,Brown Jennifer R.⁴,Byrd John C.⁵,Wagner-Johnston Nina D.⁶,Coutre Steve E.⁷,Benson Don M.⁵,Peterman Sissy⁸,Cho Yoonjin⁸,Webb Heather K.⁸,Johnson David M.⁸,Yu Albert S.⁸,Ulrich Roger G.⁸,Godfrey Wayne R.⁸,Miller Langdon L.⁸,Spurgeon Stephen E.⁹

Affiliation:

1. Sarah Cannon Research Institute, Nashville, TN;

2. University of Wisconsin Carbone Cancer Center, Madison, WI;

3. Weill Cornell Medical College, New York, NY;

4. Dana-Farber Cancer Institute, Boston, MA;

5. The Ohio State University, Columbus, OH;

6. Washington University School of Medicine, St. Louis, MO;

7. Stanford University Cancer Center, Stanford, CA;

8. Gilead Sciences, Seattle, WA; and

9. Oregon Health and Sciences University, Portland, OR

Abstract

Key Points This clinical study assessed idelalisib, a selective PI3Kδ inhibitor, in 64 patients with relapsed, indolent non-Hodgkin lymphoma. Idelalisib treatment rapidly induced durable disease responses in heavily pretreated patients with a favorable safety profile.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/22/3406/1377553/3406.pdf

Reference35 articles.

1. Non-Hodgkin lymphoma.;Shankland;Lancet,2012

2. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas.;Horning;Semin Oncol,1993

3. WHO Classification of Tumours of Haematopoietic and Lympoid Tissues.;Swerdlow,2008

4. Cancer statistics, 2012.;Siegel;CA Cancer J Clin,2012

5. National Cancer Institute. Estimated New Cancer Causes and Deaths for 2013. http://seer.cancer.gov/csr/1975_2010/results_merged/sect_01_overview.pdf. Accessed June 14, 2013

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose optimization for cancer treatments with considerations for late-onset toxicities;Clinical Trials;2024-04-09

2. Targeted therapies for follicular lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

3. Synthesis and application of small molecules approved for the treatment of lymphoma;European Journal of Medicinal Chemistry;2023-12

4. Targeting phosphoinositide signaling in cancer: relevant techniques to study lipids and novel avenues for therapeutic intervention;Frontiers in Cell and Developmental Biology;2023-10-25

5. Development of PI3Kγ selective inhibitors: the strategies and application;Acta Pharmacologica Sinica;2023-10-06